Demographic and participant characteristics at baseline
| . | Riliprubart . | ||
|---|---|---|---|
| 15 mg/kg IV (n = 6) . | 30 mg/kg IV (n = 6) . | All (N = 12) . | |
| Age (y) | |||
| Mean (SD) | 68.5 (8.5) | 66.3 (6.7) | 67.4 (7.4) |
| Median (range) | 70.0 (56-80) | 68.5 (54-72) | 69.0 (54-80) |
| Sex (n [%]) | |||
| Female | 6 (100) | 5 (83.3) | 11 (91.7) |
| Male | 0 | 1 (16.7) | 1 (8.3) |
| Geographic location (n [%]) | |||
| Germany | 0 | 3 (50.0) | 3 (25.0) |
| Italy | 1 (16.7) | 1 (16.7) | 2 (16.7) |
| The Netherlands | 3 (50.0) | 0 | 3 (25.0) |
| Norway | 0 | 1 (16.7) | 1 (8.3) |
| United Kingdom | 2 (33.3) | 1 (16.7) | 3 (25.0) |
| Prior concomitant treatments (n [%]) | |||
| Antithrombotic agents | 5 (83.3) | 2 (33.3) | 7 (58.3) |
| Corticosteroids for systematic use | 2 (33.3) | 0 | 2 (16.7) |
| Hemoglobin (g/dL) | |||
| Mean (SD) | 8.59 (2.15) | 9.73 (0.66) | 9.16 (1.63) |
| Median (range) | 9.22 (4.8-10.5) | 9.60 (9.0-10.9) | 9.60 (4.8-10.9) |
| Bilirubin (μmol) | |||
| Mean (SD) | 35.91 (23.64) | 21.18 (6.04) | 28.54 (18.16) |
| Median (range) | 33.94 (7.9-77.5) | 21.72 (13.3-29.2) | 24.54 (7.9-77.5) |
| Reticulocytes (109/L), (n [%]) | 3 (50.0) | 6 (100) | 9 (75.0) |
| Mean (SD) | 148.6 (46.5) | 138.8 (78.5) | 142.0 (66.5) |
| Median (range) | 175.4 (94.9-175.5) | 135.0 (33.1-235.5) | 156.0 (33.1-235.5) |
| Lactate dehydrogenase (IU/L), (n [%]) | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Mean (SD) | 273.8 (92.6) | 386.6 (320.1) | 330.2 (230.0) |
| Median (range) | 268 (159-402) | 292 (191-952) | 280 (159-952) |
| . | Riliprubart . | ||
|---|---|---|---|
| 15 mg/kg IV (n = 6) . | 30 mg/kg IV (n = 6) . | All (N = 12) . | |
| Age (y) | |||
| Mean (SD) | 68.5 (8.5) | 66.3 (6.7) | 67.4 (7.4) |
| Median (range) | 70.0 (56-80) | 68.5 (54-72) | 69.0 (54-80) |
| Sex (n [%]) | |||
| Female | 6 (100) | 5 (83.3) | 11 (91.7) |
| Male | 0 | 1 (16.7) | 1 (8.3) |
| Geographic location (n [%]) | |||
| Germany | 0 | 3 (50.0) | 3 (25.0) |
| Italy | 1 (16.7) | 1 (16.7) | 2 (16.7) |
| The Netherlands | 3 (50.0) | 0 | 3 (25.0) |
| Norway | 0 | 1 (16.7) | 1 (8.3) |
| United Kingdom | 2 (33.3) | 1 (16.7) | 3 (25.0) |
| Prior concomitant treatments (n [%]) | |||
| Antithrombotic agents | 5 (83.3) | 2 (33.3) | 7 (58.3) |
| Corticosteroids for systematic use | 2 (33.3) | 0 | 2 (16.7) |
| Hemoglobin (g/dL) | |||
| Mean (SD) | 8.59 (2.15) | 9.73 (0.66) | 9.16 (1.63) |
| Median (range) | 9.22 (4.8-10.5) | 9.60 (9.0-10.9) | 9.60 (4.8-10.9) |
| Bilirubin (μmol) | |||
| Mean (SD) | 35.91 (23.64) | 21.18 (6.04) | 28.54 (18.16) |
| Median (range) | 33.94 (7.9-77.5) | 21.72 (13.3-29.2) | 24.54 (7.9-77.5) |
| Reticulocytes (109/L), (n [%]) | 3 (50.0) | 6 (100) | 9 (75.0) |
| Mean (SD) | 148.6 (46.5) | 138.8 (78.5) | 142.0 (66.5) |
| Median (range) | 175.4 (94.9-175.5) | 135.0 (33.1-235.5) | 156.0 (33.1-235.5) |
| Lactate dehydrogenase (IU/L), (n [%]) | 5 (83.3) | 5 (83.3) | 10 (83.3) |
| Mean (SD) | 273.8 (92.6) | 386.6 (320.1) | 330.2 (230.0) |
| Median (range) | 268 (159-402) | 292 (191-952) | 280 (159-952) |
SD, standard deviation.